EGFR

This story has been updated from a previous version to include information about Biocartis' newly branded MDx platform and AACR presentation.

Researchers from Johns Hopkins have identified a marker, Mig6, that in early studies has been able to predict longer survival among patients taking the EGFR tyrosine kinase inhibitors gefitinib (Astra Zeneca's Iressa) and erlotinib (Genenetech's Tarceva).

Originally published May 14.
Smoking, most people have come to accept, is a major cause of lung cancer. But each year in the US, up to 24,000 men and women who have never smoked still end up dying from the disease.

Originally published May 7.

In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.

Originally published April 8.

This article has been updated from an earlier version with additional information from Qiagen on its PMA filing for an EGFR mutation companion test.

Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.

Using a pharmacogenetic strategy to home in on a molecularly defined non-small cell lung cancer patient population, researchers have shown in a clinical trial that the investigational EGFR inhibitor afatinib significantly prolongs survival in patients with EGFR-mutated tumors.

Eli Lilly said last week that it received a complete response letter from the US Food and Drug Administration declining its application to market Erbitux as a first-line treatment for non-small cell lung cancer.